263 related articles for article (PubMed ID: 35737298)
1. Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.
Buonato JM; Edwards JP; Zaritskaya L; Witter AR; Gupta A; LaFleur DW; Tice DA; Richman LK; Hilbert DM
Mol Cancer Ther; 2022 Jul; 21(7):1171-1183. PubMed ID: 35737298
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault MJ; Bishop MR; Rosenblatt J; O'Donnell EK; Raje N; Cook D; Yee AJ; Logan E; Avigan DE; Jakubowiak A; Shaw K; Daley H; Nikiforow S; Griffin F; Cornwell C; Shen A; Heery C; Maus MV
Blood Adv; 2023 Mar; 7(5):768-777. PubMed ID: 35468618
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract][Full Text] [Related]
5. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
6. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
Lam N; Trinklein ND; Buelow B; Patterson GH; Ojha N; Kochenderfer JN
Nat Commun; 2020 Jan; 11(1):283. PubMed ID: 31941907
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
8. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
9. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
Lu Q; Li H; Wu Z; Zhu Z; Zhang Z; Yang D; Tong A
J Nanobiotechnology; 2024 May; 22(1):279. PubMed ID: 38783333
[TBL] [Abstract][Full Text] [Related]
10. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
[TBL] [Abstract][Full Text] [Related]
12. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.
Ouyang W; Jin SW; Xu N; Liu WY; Zhao H; Zhang L; Kang L; Tao Y; Liu Y; Wang Y; Wang J; Liu F; Yu L; Liu Z; Mi JQ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38589248
[TBL] [Abstract][Full Text] [Related]
13. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
14. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
[TBL] [Abstract][Full Text] [Related]
15. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
16. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
[No Abstract] [Full Text] [Related]
17. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
19. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
20. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
